Cytarabine treatment of human T-lymphoid cells induces decreased HIV-1 receptor expression and reduced HIV-1 susceptibility.
Continuous cultivation of T-lymphoid C8166 cells in the presence of pharmacological relevant concentration of cytarabine (Ara-C) results in significantly decreased expression of CD4 and CXCR4 molecules, the major cellular receptor and co-receptor of T-lymphotropic HIV-1 isolates. This change in receptor expression leads to decreased susceptibility of Ara-C resistant cells to HIV-1 infection demonstrated by reduced binding and penetration of HI-virus.
Gröschel
B
B
Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt/M, Germany.
Kaufmann
A
A
Cinatl
J
J
Doerr
H W
HW
Cinatl
J
J
D000998:Antiviral Agents / Q000494:pharmacology*; D015704:CD4 Antigens / Q000096:biosynthesis / Q000235:genetics; D003561:Cytarabine / Q000494:pharmacology*; D015870:Gene Expression; D015497:HIV-1; D006801:Humans; D015728:Receptors, HIV / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism / Q000821:virology
D000998:Antiviral Agents; D015704:CD4 Antigens; D015728:Receptors, HIV; D003561:Cytarabine